References Chapter 1

  1. Nardell Edward, personal communication, Partners In Health and Harvard School of Public Health, Boston USA, October 2012.

  2. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 1980Jun.;121(6):939–49.

  3. Fortun J, Martin-Davila P, Molina A, Navas E, Hermida JM, Cobo J, et al. Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? J Antimicrob Chemother. 2007Feb.27;59(4):794–8.

  4. Iseman MD. A clinician's guide to tuberculosis. Lippincott Williams & Wilkins; 2000. pp.69.

  5. Bloom BR. Tuberculosis: pathogenesis, protection, and control. ASM press; 1994. pp.459–83.

  6. Nadia Ait-Khaled, Donald A. Enarson. Tuberculosis: A manual for Medical Students. World Health Organization. Geneva. 2003.

  7. World Health Organization. Multidrug and Extensively Drug-resistant TB (M/XDR-TB) 2010 Global Report on Surveillance and Response. World Health Organization. Geneva. (WHO/HTM/TB/2010.3).

  8. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. LWW; 2006;43(1):42–6.

  9. Grzybowski S. Tuberculosis. A look at the world situation. Chest. 1983Dec.;84(6):756–61.

  10. World Health Organization. Global Tuberculosis Control 2011. World Health Organization. Geneva. (WHO/HTM/TB/2011.16).

  11. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999Aug.18;282(7):677–86.

  12. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 2003 May12;163(9):1009–21.

  13. Lanckriet C, Lévy-Bruhl D, Bingono E, Siopathis RM, Guérin N. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui. Int J Epidemiol. 1995Oct.;24(5):1042–9.

  14. Barreto ML, Pereira SM, Pilger D, Cruz AA, Cunha SS, Sant’Anna C, et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: Second report of the BCG-REVAC cluster-randomised trial. Vaccine. Elsevier Ltd; 2011 Jul.12;29(31):4875–7.

  15. Packe GE, Innes JA. Protective effect of BCG vaccination in infant Asians: a case-control study. Arch Dis Child. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health; 1988;63(3):277–81.

  16. Padungchan S, Konjanart S, Kasiratta S, Daramas S, Dam ten HG. The effectiveness of BCG vaccination of the newborn against childhood tuberculosis in Bangkok. B World Health Organ. 1986;64(2):247–58.

  17. Lietman T, Blower SM. Potential Impact of Tuberculosis Vaccines as Epidemic Control Agents. Clinical Infectious Diseases 2000;30(Suppl 3):S316–22.

  18. Di Palma S. Tuberculosis and the BCG Vaccine: Not Quite Good Enough. Science Creative Quarterly. Issue 6, 2011.

  19. World Health Organization. Global Tuberculosis Report 2012. World Health Organization. 2012. WHO/HTM/TB/2012.6.